<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900729</url>
  </required_header>
  <id_info>
    <org_study_id>WiseGo-CT-1601</org_study_id>
    <nct_id>NCT02900729</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Renal Denervation for Resistant Hypertension</brief_title>
  <official_title>A Prospective Multicenter Randomized Controlled Trial of Efficacy and Safety of Renal Denervation for Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai WiseGain Medical Devices Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai WiseGain Medical Devices Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension represents a significant global public health problem, contributing to vascular
      and renal morbidity, cardiovascular mortality, and economic burden. For a mostly asymptomatic
      disease, there is a huge challenge to maintain a good adherence and longtime persistence of
      drug use so as to adequately control it. Even so, a significant proportion of patients will
      develop resistant hypertension. In recent years, renal denervation has been argued as an
      effective means to address blood pressure problem in several non-Chinese clinical trials. The
      technique is to deliver low level radiofrequency energy through the renal artery wall to
      target the sympathetic nervous system and then modulate blood pressure.

      Shanghai WiseGain Medical Devices Co., LTD has developed the WiseGo Catheter System, which is
      an irrigated radiofrequency ablation Catheter. With this Catheter, it is expected to improve
      blood pressure status among patients with resistant hypertension failing polypharmacy. The
      purpose of this randomized control trial is to obtain an assessment of the efficacy and
      safety of WiseGo renal denervation technique in the presence of three standard
      antihypertensive medications in Chinese patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average 24-hour systolic blood pressure by ambulatory blood pressure monitoring from baseline</measure>
    <time_frame>3 months post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of achieving target blood pressure</measure>
    <time_frame>6 months post-randomization</time_frame>
    <description>Target blood pressure is defined as daytime ambulatory blood pressure &lt;135/85mmHg, nighttime ambulatory blood pressure &lt;120/70mmHg or average 24-hour ambulatory blood pressure &lt;130/80mmHg, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daytime and nighttime ambulatory systolic blood pressure from baseline</measure>
    <time_frame>3 months post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24 hour average, daytime and nighttime ambulatory diastolic blood pressure from baseline</measure>
    <time_frame>3 months post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine from baseline</measure>
    <time_frame>6 months post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse event</measure>
    <time_frame>Through study completion, up to 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in 24 hour average, daytime and nighttime ambulatory systolic/diastolic blood pressure from baseline</measure>
    <time_frame>6 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in office systolic/diastolic blood pressure from baseline</measure>
    <time_frame>6 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in patient-recorded home systolic/diastolic blood pressure from baseline</measure>
    <time_frame>6 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of achieving reductions of ≥ 5 mmHg, ≥ 10 mmHg, ≥15 mmHg, and ≥ 20 mmHg in blood pressure, including ambulatory, office and home blood pressure</measure>
    <time_frame>6 months post-randomization</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidences of substantially adjusting antihypertensive medications</measure>
    <time_frame>6 months post-randomization</time_frame>
    <description>A substantial adjustment of antihypertensive medications is defined as any changes in number of antihypertensive medications, or type of antihypertensive medications, or ≥ 50% dose change in any ongoing antihypertensive medications in the last two weeks.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Renal Denervation plus Medications</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medications</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiofrequency ablation catheter</intervention_name>
    <description>Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.</description>
    <arm_group_label>Renal Denervation plus Medications</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine, losartan potassium and hydrochlorothiazide</intervention_name>
    <description>Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.</description>
    <arm_group_label>Renal Denervation plus Medications</arm_group_label>
    <arm_group_label>Medications</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject with primary hypertension has 24-hour ambulatory systolic blood pressure ≥ 135
             mmHg and office systolic blood pressure ≥ 140 mmHg /office diastolic blood pressure ≥
             90 mmHg after a 4-week standardised triple therapy.

          2. Subject is ≥ 18 and &lt; 80 years old at time of randomization.

          3. Subject agrees to have all study procedures performed, and willing to provide written
             informed consent to participate in this clinical study.

        Exclusion Criteria:

          1. Subject has acute or serious systemic infection.

          2. Subject has a history of renal artery interventional therapy.

          3. Subject lacks suitable renal artery anatomy for percutaneous renal sympathetic nerve
             radiofrequency ablation surgery, including not limited to a presence of serious aorta
             or renal-artery tortuosity or renal-artery stenosis.

          4. Subject has experienced a myocardial infarction, unstable angina pectoris, syncope, or
             a cerebrovascular accident within three months of the screening period, or has
             widespread atherosclerosis, with documented intravascular thrombosis.

          5. Subject has aortic dissection aneurysm.

          6. Subject has primary pulmonary hypertension.

          7. Subject has an estimated glomerular filtration rate of less than 40 mL/min/1.73m²
             according to Modification of Diet in Renal Disease formula.

          8. Subject had a definite diagnose of coronary heart disease requiring beta blockers

          9. Subject has a Class III - IV of heart failure or left ventricular ejection fraction
             &lt;45%.

         10. Subject had atrial fibrillation.

         11. Subject has a significant bleeding tendency or blood system disease(s).

         12. Subject has a malignancy or end-stage disease(s).

         13. Subject has secondary hypertension.

         14. Subject has type 1 diabetes mellitus.

         15. Subject has other conditions inappropriate for participation at the investigator's
             discretion.

         16. Subject has a medical ethics of concern at the investigator's discretion, such as a
             presence of 24-hour Ambulatory Blood Pressure Monitoring average systolic blood
             pressure ≥ 170 mmHg after a 4-week standardised triple therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital affiliated to Fu Dan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Chen, Dr.</last_name>
    <phone>86-21-61400976</phone>
    <email>helen6_2@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhihui Zhang, Dr.</last_name>
      <email>zhangzhihui0869@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoyan Wang, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fu Dan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junbo Ge, Dr.</last_name>
      <email>ge.junbo@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Li Shen, Dr.</last_name>
      <email>shen.li@zs-hospital.sh.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital affiliated to Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianxian Zhao, Dr.</last_name>
      <email>13601713431@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhifu Guo, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Putuo Hospital affiliated to Shanghai Traditional Chinese Medicine University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zongjun Liu, Dr.</last_name>
      <email>lzj72@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia Shi, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiyi Fang, Dr.</last_name>
      <email>fwychest@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Shaofeng Guan, Dr.</last_name>
      <email>gsf@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Changqian Wang, Dr.</last_name>
      <email>wcqian@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhaofang Yin, Dr.</last_name>
      <email>13072103901@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingbo Li, Dr.</last_name>
      <email>jbli@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yesheng Pan, Dr.</last_name>
      <email>panyesheng@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xuebo Liu, Dr.</last_name>
      <email>lxb70@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yang Liu, Dr.</last_name>
      <email>961165@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine Chongming Branch</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingmin Lu, Dr.</last_name>
      <email>lymkk@sohu.com</email>
    </contact>
    <contact_backup>
      <last_name>Shuxin Hou, Dr.</last_name>
      <email>1461396934@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guosheng Fu, Dr.</last_name>
      <email>fugs@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chenyang Jiang, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Hospital affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianan Wang, Dr.</last_name>
      <email>wang_jian_an@tom.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Jiang, Dr.</last_name>
      <email>drjayj@Hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianjun Jiang, Dr.</last_name>
      <email>taizhoujiangjj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yafei Mi, Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Hospital affiliated to Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weijian Huang, Dr.</last_name>
      <email>weijianhuang69@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhouqing Huang, Dr.</last_name>
      <email>susiehzq@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401. doi: 10.1056/NEJMoa1402670. Epub 2014 Mar 29.</citation>
    <PMID>24678939</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

